Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Parexel Biotech

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab

            Therapeutic Area: Gastroenterology Product Name: TZLS-401

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Tiziana Life Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 11, 2020

            Details:

            This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. and Europe.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Interferon Beta-1A

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SNG001

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Synairgen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 20, 2020

            Details:

            Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen.